<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Nephrol Dial Transplant</journal-id><journal-id journal-id-type="publisher-id">ndt</journal-id><journal-id journal-id-type="hwp">ndt</journal-id><journal-title-group><journal-title>Nephrology Dialysis Transplantation</journal-title></journal-title-group><issn pub-type="ppub">0931-0509</issn><issn pub-type="epub">1460-2385</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1093/ndt/gfp079</article-id><article-id pub-id-type="publisher-id">gfp079</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Nephrology</subject></subj-group></article-categories><title-group><article-title>Genetic variation in the transforming growth factor-&#x003b2;1 gene is&#x000a0;associated with susceptibility to IgA nephropathy</article-title><alt-title alt-title-type="left-running">M. T. Vuong <italic>et al.</italic></alt-title><alt-title alt-title-type="right-running">TGFB1 genetics of IgA nephropathy</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Vuong</surname><given-names>Mai Tuyet</given-names></name><xref ref-type="aff" rid="af1 af2 af3">1,2,3</xref></contrib><contrib contrib-type="author"><name><surname>Lundberg</surname><given-names>Sigrid</given-names></name><xref ref-type="aff" rid="af4">4</xref></contrib><contrib contrib-type="author"><name><surname>Gunnarsson</surname><given-names>Iva</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wramner</surname><given-names>Lars</given-names></name><xref ref-type="aff" rid="af5">5</xref></contrib><contrib contrib-type="author"><name><surname>Seddighzadeh</surname><given-names>Maria</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hahn-Zoric</surname><given-names>Mirjana</given-names></name><xref ref-type="aff" rid="af6">6</xref></contrib><contrib contrib-type="author"><name><surname>Fernstr&#x000f6;m</surname><given-names>Anders</given-names></name><xref ref-type="aff" rid="af7">7</xref></contrib><contrib contrib-type="author"><name><surname>Hanson</surname><given-names>Lars &#x000c5;</given-names></name><xref ref-type="aff" rid="af6">6</xref></contrib><contrib contrib-type="author"><name><surname>Do</surname><given-names>Lieu Thi</given-names></name><xref ref-type="aff" rid="af3">3</xref></contrib><contrib contrib-type="author"><name><surname>Jacobson</surname><given-names>Stefan H.</given-names></name><xref ref-type="aff" rid="af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Padyukov</surname><given-names>Leonid</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib></contrib-group><aff id="af1"><label>1</label><addr-line>Department of Medicine, Rheumatology Unit</addr-line></aff><aff id="af2"><label>2</label><addr-line>Department of Nephrology</addr-line>, <institution>Danderyd Hospital</institution>, <addr-line>Karolinska Institutet, Stockholm</addr-line>, <country>Sweden</country></aff><aff id="af3"><label>3</label><addr-line>Department of Internal Medicine</addr-line>, <institution>Hanoi Medical University</institution>, <addr-line>Hanoi, Vietnam</addr-line></aff><aff id="af4"><label>4</label><addr-line>Department of Medicine, Nephrology Unit</addr-line>, <institution>Karolinska University Hospital</institution>, <addr-line>Stockholm</addr-line></aff><aff id="af5"><label>5</label><addr-line>Transplantation Center</addr-line>, <institution>Sahlgrenska University Hospital</institution></aff><aff id="af6"><label>6</label><addr-line>Department of Clinical Immunology</addr-line>, <institution>Sahlgrenska University Hospital and Academy</institution>, <addr-line>G&#x000f6;teborg</addr-line></aff><aff id="af7"><label>7</label><addr-line>Department of Nephrology</addr-line>, <institution>Link&#x000f6;ping University Hospital</institution>, <addr-line>Link&#x000f6;ping</addr-line>, <country>Sweden</country></aff><author-notes><corresp><italic>Correspondence and offprint requests to</italic>: Leonid Padyukov; E-mail: <email>leonid.padyukov@ki.se</email></corresp></author-notes><pub-date pub-type="ppub"><month>10</month><year>2009</year></pub-date><pub-date pub-type="epub"><day>3</day><month>3</month><year>2009</year></pub-date><pub-date pub-type="pmc-release"><day>3</day><month>3</month><year>2009</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>24</volume><issue>10</issue><fpage>3061</fpage><lpage>3067</lpage><history><date date-type="received"><day>7</day><month>5</month><year>2008</year></date><date date-type="accepted"><day>3</day><month>2</month><year>2009</year></date></history><permissions><copyright-statement>&#x000a9; The Author [2009]. Published by Oxford University Press [on behalf of ERA-EDTA].</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Oxford University Press</copyright-holder><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/2.0/uk/"><license-p><!--CREATIVE COMMONS-->This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/2.5/uk/">http://creativecommons.org/licenses/by-nc/2.5/uk/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p><bold>Background.</bold> There is growing evidence of genetic risk for susceptibility to IgA nephropathy. Among several candidate genes related to immunological regulation in renal tissue, <italic>TGFB1</italic> is known to be a contributor to proliferation and the development of fibrosis.</p><p><bold>Methods.</bold> We analysed several SNPs in a region of this gene using 212 DNA samples from biopsy-proven IgA nephropathy patients, 146 men and 66 women and 477 healthy age-matched controls (321 men and 156 women) from the same population in Sweden.</p><p><bold>Results.</bold> Frequencies of four out of five selected SNPs (rs6957, rs2241715, rs1800471, rs1982073 and rs1800469) were found to significantly differ between male patients and male controls in a co-dominant model (corrected <italic>P</italic> &#x02264; 0.05) and of two SNPs (rs1982073 and rs1800469) in the allelic model (<italic>P</italic> &#x02264; 0.05 in 100&#x02009;000 permutation test). Haplotype analysis for five selected SNPs revealed a significant association of TGGCG with protective effect (<italic>P</italic> = 0.0012, empirical <italic>P</italic> = 0.006, 100&#x02009;000 permutations) and of CTGTA with susceptibility effect (<italic>P</italic> = 0.0018, empirical <italic>P</italic> = 0.008, 100&#x02009;000 permutations). In our study, no association with <italic>TGFB1</italic> variations was found when comparing female patients and female controls. No association was found for <italic>TGFB1</italic> markers with disease progression for selected individuals from the patient's group. In addition, meta-analysis performed for SNP rs1982073 for combined patients and controls from our study together with published data from two independent studies showed a significant association.</p><p><bold>Conclusions.</bold> Our experimental data together with the meta-analysis suggest <italic>TGFB1</italic> as an important candidate gene for further biological studies of IgA nephropathy and as a possible target for therapy. Our data also indicate a possibility of a gender effect in the genetic background of IgA nephropathy.</p></abstract><kwd-group><title>Keywords</title><kwd>IgA nephropathy</kwd><kwd>polymorphism</kwd><kwd>SNP</kwd><kwd>TGFB1</kwd></kwd-group></article-meta></front><body><sec id="S1" sec-type="intro"><title>Introduction</title><p>IgA nephropathy is the most common form of glomerulonephritis identified in all regions of the world where renal biopsy is widely practiced. Evidence derived from experimental models of spontaneous IgA nephropathy and studies of the genetics, familial occurrence and racial differences in prevalence support the influence of genetic factors in the development and progression of IgA nephropathy [<xref ref-type="bibr" rid="R1 R2 R3">1&#x02013;3</xref>]. IgA nephropathy in Caucasian populations was shown to be more prevalent in men; the ratio of males to females with IgA nephropathy is around 6:1 in northern Europe and the United States [<xref ref-type="bibr" rid="R4">4</xref>]. Poor prognostic factors for progression of renal damage in patients with IgA nephropathy are male gender, older age, presence of hypertension, moderate or severe proteinuria and severe renal lesions [<xref ref-type="bibr" rid="R1">1</xref>].</p><p>Transforming growth factor-&#x003b2;1 (TGF&#x003b2;1) is a multifunctional cytokine that mediates cell proliferation, differentiation and other functions in different cell types. TGF&#x003b2;1 signalling is an essential mechanism in isotype switching to immunoglobulin A in B lymphocytes and up-regulates IgA production in general [<xref ref-type="bibr" rid="R5">5</xref>]. TGF&#x003b2;1 contributes to the expansion of mesangial matrix, development of fibrosis and cell proliferation both in animal models and in human diseases [<xref ref-type="bibr" rid="R6 R7">6,7</xref>]. The kidney seems to be particularly sensitive to the powerful fibrogenic actions of TGF&#x003b2;1 that may contribute to fibrosis in most forms of renal diseases, leading to renal impairment and decreased renal function [<xref ref-type="bibr" rid="R8 R9">8,9</xref>].</p><p>The TGF&#x003b2;1 gene, <italic>TGFB1</italic>, is located at the human chromosome 19q13.1-3 (omim 190180). There are several indications that genetic polymorphism of this gene is involved in the development of fibrotic diseases [<xref ref-type="bibr" rid="R8">8</xref>,<xref ref-type="bibr" rid="R10">10</xref>,<xref ref-type="bibr" rid="R11">11</xref>] and may regulate TGF&#x003b2;1 production [<xref ref-type="bibr" rid="R12">12</xref>]. Four previous studies of <italic>TGFB1</italic> polymorphisms have demonstrated possible associations between susceptibility and/or severity of IgA nephropathy, but the results have so far been inconsistent [<xref ref-type="bibr" rid="R9 R10">9,10</xref>,<xref ref-type="bibr" rid="R13 R14">13,14</xref>].</p><p>In the present study, 212 unrelated patients with biopsy-proven IgA nephropathy and 477 healthy subjects were selected for studies of five various polymorphisms in the <italic>TGFB1</italic> gene with consideration to gender. In addition, a meta-analysis including previous studies was performed in order to clarify the role of TGF&#x003b2;1 as a possible susceptibility factor in IgA nephropathy.</p></sec><sec id="S2" sec-type="methods"><title>Materials and methods</title><sec id="S2-1"><title>Subjects</title><p>A total of 212 unrelated patients (146 males and 66 females), mean age 38.5 &#x000b1; 14.4 (range 17&#x02013;77 years) with biopsy-proven IgA nephropathy, all self-reported Caucasians, and 477 individually sex- and age-matched healthy Caucasians from a Swedish population (321 males and 156 females), mean age 44.8 &#x000b1; 13.0 (range 18&#x02013;80 years), were included in the present investigation. The patients were recruited from the Department of Nephrology at the Karolinska University Hospital (<italic>n</italic> = 117), Danderyd Hospital (<italic>n</italic>&#x000a0;= 31), Sk&#x000f6;vde Hospital (<italic>n</italic> = 36) and Link&#x000f6;ping Hospital (<italic>n</italic> = 28), representing a population from the central part of Sweden. Patients with Henoch-Sch&#x000f6;nlein purpura and other forms of glomerulonephritis were not included in the study. For known information about kidney function in the patients at the time of diagnosis, see Table <xref ref-type="table" rid="T1">1</xref>.</p><table-wrap id="T1" position="float"><label>Table&#x000a0;1</label><caption><p>Glomerular filtration rate of the patients in the different stages of chronic kidney disease<sup>a</sup></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">&#x0003e;90 ml/min</th><th align="left" rowspan="1" colspan="1">90&#x02013;60 ml/min</th><th align="left" rowspan="1" colspan="1">30&#x02013;59 ml/min</th><th align="left" rowspan="1" colspan="1">15&#x02013;29 ml/min</th><th align="left" rowspan="1" colspan="1">&#x0003c;15 ml/min</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Males, <italic>n</italic> = 77 (73.3%)</td><td rowspan="1" colspan="1">19 (18.1%)</td><td rowspan="1" colspan="1">28 (26.7%)</td><td rowspan="1" colspan="1">20 (19.0%)</td><td rowspan="1" colspan="1">6 (5.7%)</td><td rowspan="1" colspan="1">4 (3.8%)</td></tr><tr><td rowspan="1" colspan="1">Females, <italic>n</italic> = 28 (26.7%)</td><td rowspan="1" colspan="1">4 (3.8%)</td><td rowspan="1" colspan="1">15 (14.3%)</td><td rowspan="1" colspan="1">6 (5.7%)</td><td rowspan="1" colspan="1">2 (1.9%)</td><td rowspan="1" colspan="1">1 (1%)</td></tr><tr><td rowspan="1" colspan="1">Total, <italic>n</italic> = 105 (100%)</td><td rowspan="1" colspan="1">23 (21.9%)</td><td rowspan="1" colspan="1">43 (41.0%)</td><td rowspan="1" colspan="1">26 (24.7%)</td><td rowspan="1" colspan="1">8 (7.6%)</td><td rowspan="1" colspan="1">5 (4.8%)</td></tr></tbody></table><table-wrap-foot><fn id="T1TFN1"><p><sup>a</sup>Calculated for individuals with available clinical data.</p></fn></table-wrap-foot></table-wrap><p>All patients gave informed consent, and the study was approved by the Ethics Committee of the Karolinska Hospital, Stockholm, Sweden.</p></sec><sec id="S2-2"><title>Disease severity</title><p>One hundred and seventeen patients from the Karolinska University Hospital, who had been followed up for up to 12 years since renal biopsy, were investigated for the correlation between <italic>TGFB1</italic> genotype and disease severity. The average age of these patients at the time of renal biopsy was 37.0 &#x000b1; 13.2 years (range 17&#x02013;77 years).</p><p>Glomerular filtration rate (GFR) was estimated from yearly serum creatinine measurements using the Modification of Diet in Renal Disease (MDRD) equation [<xref ref-type="bibr" rid="R15">15</xref>]. To investigate the correlation between genotype and disease severity, we used the following criteria: for benign disease, loss of GFR of &#x0003c;2 ml/min/year, for moderate progression loss of GFR of &#x02265;2 to &#x0003c;5 ml/min/year or the progression to chronic kidney disease (CKD) stage 3 (GFR = 30&#x02013;59 ml/min/1.73 m<sup>2</sup>), and for severe progression, loss of GFR of &#x02265;5 ml/min/year or reaching CDK stage 4 or 5 (GFR = 15&#x02013;29 ml/min/1.73 m<sup>2</sup> and GFR&#x0003c;15 ml/min/1.73 m<sup>2</sup>).</p></sec><sec id="S2-3"><title>Selection of markers</title><p>The <italic>TGFB1</italic> gene in the HapMap database represents a sequence at chromosome 19q13.1 between two recombination blocks. We succeeded with five reproducible assays: in the promoter region at position &#x02212;509, rs1800469 (C-509T), in the downstream 3&#x02032; genomic region, rs6957, in the intron, rs2241715, and two in the signal sequence of exon 1, rs1800471 (C915G or codon 25, arginine&#x02192;proline) and rs1982073 (T869C or codon 10, leucine&#x02192;proline). More detailed information of all selected SNPs with the minor allele frequencies is presented in Table <xref ref-type="table" rid="T2">2</xref>.</p><table-wrap id="T2" position="float"><label>Table&#x000a0;2</label><caption><p>Polymorphisms of the <italic>TGFB1</italic> gene in IgA nephropathy patients</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Chromosome</th><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Heterozygosity</th><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/></tr><tr><th align="left" rowspan="1" colspan="1">SNP</th><th align="left" rowspan="1" colspan="1">Position</th><th align="left" rowspan="1" colspan="1">Alternative name</th><th align="left" rowspan="1" colspan="1">position</th><th align="left" rowspan="1" colspan="1">Alleles</th><th align="left" rowspan="1" colspan="1">from NCBI</th><th align="left" rowspan="1" colspan="1">MAF<sup>a</sup></th><th align="left" rowspan="1" colspan="1">ABI assay</th><th align="left" rowspan="1" colspan="1">Methods</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">rs6957</td><td rowspan="1" colspan="1">Downstream 3&#x02032; genomic region</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">46522446</td><td rowspan="1" colspan="1">C/T</td><td rowspan="1" colspan="1">0.414</td><td rowspan="1" colspan="1">0.167</td><td rowspan="1" colspan="1">C___7818385_10</td><td rowspan="1" colspan="1">TaqMan</td></tr><tr><td rowspan="1" colspan="1">rs2241715</td><td rowspan="1" colspan="1">Intron 1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">46548726</td><td rowspan="1" colspan="1">G/T</td><td rowspan="1" colspan="1">0.467</td><td rowspan="1" colspan="1">0.289</td><td rowspan="1" colspan="1">Assay by design</td><td rowspan="1" colspan="1">TaqMan</td></tr><tr><td rowspan="1" colspan="1">rs1800471</td><td rowspan="1" colspan="1">Signal sequence of exone 1</td><td rowspan="1" colspan="1">Codon 25 or G915C (arginine&#x02192;proline)</td><td rowspan="1" colspan="1">46550716</td><td rowspan="1" colspan="1">C/G</td><td rowspan="1" colspan="1">0.112</td><td rowspan="1" colspan="1">0.081</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">REM<sup>b</sup></td></tr><tr><td rowspan="1" colspan="1">rs1982073</td><td rowspan="1" colspan="1">Signal sequence of exone 1</td><td rowspan="1" colspan="1">Codon 10 or T869C (leucine&#x02192;proline)</td><td rowspan="1" colspan="1">46550761</td><td rowspan="1" colspan="1">C/T</td><td rowspan="1" colspan="1">0.397</td><td rowspan="1" colspan="1">0.378</td><td rowspan="1" colspan="1">C___22272997_10</td><td rowspan="1" colspan="1">TaqMan</td></tr><tr><td rowspan="1" colspan="1">rs1800469</td><td rowspan="1" colspan="1">Promoter</td><td rowspan="1" colspan="1">C-509T</td><td rowspan="1" colspan="1">46552136</td><td rowspan="1" colspan="1">A/G</td><td rowspan="1" colspan="1">0.485</td><td rowspan="1" colspan="1">0.295</td><td rowspan="1" colspan="1">C___8708473_10</td><td rowspan="1" colspan="1">TaqMan</td></tr></tbody></table><table-wrap-foot><fn id="T2TFN1"><p><sup>a</sup>Minor allele frequency from current study.</p></fn><fn id="T2TFN2"><p><sup>b</sup>Restriction Endonuclease Mapping method.</p></fn></table-wrap-foot></table-wrap></sec><sec id="S2-4"><title>DNA and genotyping</title><p>DNA was extracted from EDTA blood samples (5&#x02013;10 ml) by the &#x02018;salting out&#x02019; method as described elsewhere [<xref ref-type="bibr" rid="R16">16</xref>]. To identify codon 25 allele polymorphism (rs1800471) in the <italic>TGFB1</italic> gene, the restriction endonuclease mapping method (REM) was used as previously described [<xref ref-type="bibr" rid="R16">16</xref>]. To detect other SNPs (rs6957, rs2241715, rs1982073 and rs1800469) of the <italic>TGFB1</italic> gene, the TaqMan allelic discrimination assay (Applied Biosystems, Foster City, CA, USA) was used. Three out of four assays were commercially available and one was designed for this project (Table <xref ref-type="table" rid="T2">2</xref>). TaqMan allelic discrimination was performed according to the standard protocol in a 384-well plate with 10 ng of DNA per sample. PCR was run in GeneAmp PCR System 9700 (Applied Biosystems), and the fluorescent signals from the hybridization probes were detected by a 7900 Sequence Detector (Applied Biosystems).</p><p>To assess genotyping robustness, we re-genotyped a random subset of 191 cases and controls for rs1982073 SNP using the restriction endonuclease mapping method published previously [<xref ref-type="bibr" rid="R17">17</xref>], which resulted in a 99.5% match of genotyping calls with the TaqMan assay.</p><p>All analysed markers were in Hardy&#x02013;Weinberg equilibrium. Positive rates of genotype detection were 99.9% for rs2241715, 99.3% for rs6957 and 99.6% for the rest of the SNPs.</p></sec><sec id="S2-5"><title>Statistical analysis</title><p>To assess genotype, allele and haplotype frequencies, Pearson's chi-square and/or Fisher's exact tests were performed when appropriate with SPSS 13.0 software. Haplotype analysis was carried out by HaploView [<xref ref-type="bibr" rid="R18">18</xref>], and the permutation test of this analysis was set to 100&#x02009;000 permutations for single markers and haplotypes. For meta-analysis, the Mantel&#x02013;Haenszel method was employed with a fixed effect and 95% confidence interval (95% CI) for odds ratio. Power calculation was performed for the two-tailed or one-tailed test when appropriate for 5% threshold of significance.</p></sec></sec><sec id="S3" sec-type="results"><title>Results</title><sec id="S3-1"><title>Genotype frequencies of TGFB1 polymorphisms in male and female IgA nephropathy patients and healthy controls</title><p>We genotyped 212 unrelated IgA nephropathy patients, 146 men (68.9%) and 66 women (31.1%), and 477 healthy subjects, 321 men (67.3%) and 156 women (32.7%), for five various polymorphisms of the <italic>TGFB1</italic> gene. The minor allelic frequencies (MAF) are presented in Table <xref ref-type="table" rid="T2">2</xref>. A significant difference between the genotype distribution in male IgA nephropathy patients and male healthy controls was found in a co-dominant model for all five SNPs (Table <xref ref-type="table" rid="T3">3</xref>a). After the Bonferroni correction for multiple comparisons, four out of five SNPs remained significantly associated with <italic>P</italic> &#x02264; 0.05. Genotype frequencies for studied SNPs in the female study group did not, however, show a significant difference (Table <xref ref-type="table" rid="T3">3</xref>b).</p><table-wrap id="T3" position="float"><label>Table&#x000a0;3</label><caption><p>Genotype frequencies of <italic>TGFB1</italic> polymorphisms in (a) male and (b) female IgA nephropathy patients in a co-dominant model</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th colspan="3" align="left" rowspan="1">SNPs</th><th colspan="3" align="left" rowspan="1">Genotype frequency in co-dominant model</th><th rowspan="1" colspan="1">Chi-square</th><th rowspan="1" colspan="1"><italic>P</italic>-value<sup>a</sup></th></tr></thead><tbody><tr><td colspan="8" align="left" rowspan="1">(a) Male IgA nephropathy patients</td></tr><tr><td colspan="2" align="left" rowspan="1">TGFB1 rs6957</td><td align="left" rowspan="1" colspan="1">Total<sup>b</sup></td><td align="left" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">CT</td><td align="left" rowspan="1" colspan="1">TT</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Group</td><td rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">314 (100%)</td><td rowspan="1" colspan="1">3 (1%)</td><td rowspan="1" colspan="1">85 (27%)</td><td rowspan="1" colspan="1">226 (72%)</td><td rowspan="1" colspan="1">11.5</td><td rowspan="1" colspan="1">0.003</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Patient</td><td rowspan="1" colspan="1">144 (100%)</td><td rowspan="1" colspan="1">9 (6.3%)</td><td rowspan="1" colspan="1">42 (29.1%)</td><td rowspan="1" colspan="1">93 (64.6%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td colspan="2" align="left" rowspan="1">TGFB1 rs2241715</td><td rowspan="1" colspan="1">Total</td><td rowspan="1" colspan="1">GG</td><td rowspan="1" colspan="1">GT</td><td rowspan="1" colspan="1">TT</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Group</td><td rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">315 (100%)</td><td rowspan="1" colspan="1">171 (54.3%)</td><td rowspan="1" colspan="1">120 (38.1%)</td><td rowspan="1" colspan="1">24 (7.6%)</td><td rowspan="1" colspan="1">7.4</td><td rowspan="1" colspan="1">0.02</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Patient</td><td rowspan="1" colspan="1">145 (100%)</td><td rowspan="1" colspan="1">59 (40.7%)</td><td rowspan="1" colspan="1">73 (50.3%)</td><td rowspan="1" colspan="1">13 (9%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td colspan="2" align="left" rowspan="1">TGFB1 rs1800471</td><td rowspan="1" colspan="1">Total</td><td rowspan="1" colspan="1">CC</td><td rowspan="1" colspan="1">CG</td><td rowspan="1" colspan="1">GG</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Group</td><td rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">319 (100%)</td><td rowspan="1" colspan="1">0 (0%)</td><td rowspan="1" colspan="1">48 (15%)</td><td rowspan="1" colspan="1">271 (85%)</td><td rowspan="1" colspan="1">9.1</td><td rowspan="1" colspan="1">0.01</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Patient</td><td rowspan="1" colspan="1">143 (100%)</td><td rowspan="1" colspan="1">4 (2.8%)</td><td rowspan="1" colspan="1">19 (13.3%)</td><td rowspan="1" colspan="1">120 (83.9%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td colspan="2" align="left" rowspan="1">TGFB1 rs1982073</td><td rowspan="1" colspan="1">Total</td><td rowspan="1" colspan="1">CC</td><td rowspan="1" colspan="1">CT</td><td rowspan="1" colspan="1">TT</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Group</td><td rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">314 (100%)</td><td rowspan="1" colspan="1">132 (42%)</td><td rowspan="1" colspan="1">147 (46.8%)</td><td rowspan="1" colspan="1">35 (11.2%)</td><td rowspan="1" colspan="1">9.9</td><td rowspan="1" colspan="1">0.007</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Patient</td><td rowspan="1" colspan="1">144 (100%)</td><td rowspan="1" colspan="1">40 (27.8%)</td><td rowspan="1" colspan="1">78 (54.2%)</td><td rowspan="1" colspan="1">26 (18%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td colspan="2" align="left" rowspan="1">TGFB1 rs1800469</td><td rowspan="1" colspan="1">Total</td><td rowspan="1" colspan="1">AA</td><td rowspan="1" colspan="1">AG</td><td rowspan="1" colspan="1">GG</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Group</td><td rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">314 (100%)</td><td rowspan="1" colspan="1">24 (7.6%)</td><td rowspan="1" colspan="1">120 (38.2%)</td><td rowspan="1" colspan="1">170 (54.2%)</td><td rowspan="1" colspan="1">10.2</td><td rowspan="1" colspan="1">0.006</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Patient</td><td rowspan="1" colspan="1">144 (100%)</td><td rowspan="1" colspan="1">13 (9%)</td><td rowspan="1" colspan="1">76 (52.8%)</td><td rowspan="1" colspan="1">55 (38.2%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td colspan="8" align="left" rowspan="1">(b) Female IgA nephropathy patients</td></tr><tr><th colspan="2" align="left" rowspan="1">TGFB1 rs6957</th><th align="left" rowspan="1" colspan="1">Total<sup>b</sup></th><th align="left" rowspan="1" colspan="1">CC</th><th align="left" rowspan="1" colspan="1">CT</th><th align="left" rowspan="1" colspan="1">TT</th><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Group</td><td rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">152 (100%)</td><td rowspan="1" colspan="1">4 (2.6%)</td><td rowspan="1" colspan="1">44 (28.9%)</td><td rowspan="1" colspan="1">104 (68.5%)</td><td rowspan="1" colspan="1">0.9</td><td rowspan="1" colspan="1">0.6</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Patient</td><td rowspan="1" colspan="1">65 (100%)</td><td rowspan="1" colspan="1">3 (4.6%)</td><td rowspan="1" colspan="1">16 (24.6%)</td><td rowspan="1" colspan="1">46 (70.8%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td colspan="2" align="left" rowspan="1">TGFB1 rs2241715</td><td rowspan="1" colspan="1">Total</td><td rowspan="1" colspan="1">GG</td><td rowspan="1" colspan="1">GT</td><td rowspan="1" colspan="1">TT</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Group</td><td rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">153 (100%)</td><td rowspan="1" colspan="1">75 (49%)</td><td rowspan="1" colspan="1">64 (41.8%)</td><td rowspan="1" colspan="1">14 (9.2%)</td><td rowspan="1" colspan="1">1.4</td><td rowspan="1" colspan="1">0.5</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Patient</td><td rowspan="1" colspan="1">66 (100%)</td><td rowspan="1" colspan="1">35 (53%)</td><td rowspan="1" colspan="1">28 (42.4%)</td><td rowspan="1" colspan="1">3 (4.6%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td colspan="2" align="left" rowspan="1">TGFB1 rs1800471</td><td rowspan="1" colspan="1">Total</td><td rowspan="1" colspan="1">CC</td><td rowspan="1" colspan="1">CG</td><td rowspan="1" colspan="1">GG</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Group</td><td rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">156 (100%)</td><td rowspan="1" colspan="1">0 (0%)</td><td rowspan="1" colspan="1">23 (14.7%)</td><td rowspan="1" colspan="1">133 (85.3%)</td><td rowspan="1" colspan="1">2.4</td><td rowspan="1" colspan="1">0.3</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Patient</td><td rowspan="1" colspan="1">66 (100%)</td><td rowspan="1" colspan="1">1 (1.5%)</td><td rowspan="1" colspan="1">10 (15.2%)</td><td rowspan="1" colspan="1">55 (83.3%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td colspan="2" align="left" rowspan="1">TGFB1 rs1982073</td><td rowspan="1" colspan="1">Total</td><td rowspan="1" colspan="1">CC</td><td rowspan="1" colspan="1">CT</td><td rowspan="1" colspan="1">TT</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Group</td><td rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">153 (100%)</td><td rowspan="1" colspan="1">56 (36.6%)</td><td rowspan="1" colspan="1">78 (51%)</td><td rowspan="1" colspan="1">19 (12.4%)</td><td rowspan="1" colspan="1">0.3</td><td rowspan="1" colspan="1">0.8</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Patient</td><td rowspan="1" colspan="1">66 (100%)</td><td rowspan="1" colspan="1">26 (39.4%)</td><td rowspan="1" colspan="1">31 (47%)</td><td rowspan="1" colspan="1">9 (13.6%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td colspan="2" align="left" rowspan="1">TGFB1 rs1800469</td><td rowspan="1" colspan="1">Total</td><td rowspan="1" colspan="1">AA</td><td rowspan="1" colspan="1">AG</td><td rowspan="1" colspan="1">GG</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Group</td><td rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">154 (100%)</td><td rowspan="1" colspan="1">14 (9.1%)</td><td rowspan="1" colspan="1">65 (42.2%)</td><td rowspan="1" colspan="1">75 (48.7%)</td><td rowspan="1" colspan="1">0.5</td><td rowspan="1" colspan="1">0.8</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Patient</td><td rowspan="1" colspan="1">65 (100%)</td><td rowspan="1" colspan="1">4 (6.2%)</td><td rowspan="1" colspan="1">28 (43%)</td><td rowspan="1" colspan="1">33 (50.8%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="T3TFN1"><p><sup>a</sup>Uncorrected.</p></fn><fn id="T3TFN2"><p><sup>b</sup>Total number for different variations may be different due to genotyping failure.</p></fn></table-wrap-foot></table-wrap><p>The allele and haplotype frequencies with experimental chi-square <italic>P</italic>-values and empiric <italic>P</italic>-values after permutation test are presented in Tables <xref ref-type="table" rid="T4">4</xref> and <xref ref-type="table" rid="T5">5</xref>. When comparing the frequency of alleles, we found significant differences for rs2241715, rs1982073 and rs1800469 comparing male patients and male controls (<italic>P</italic> &#x0003c; 0.02, Table&#x000a0;<xref ref-type="table" rid="T4">4</xref>a). To check for possible false positive associations, we performed a permutation test with 100&#x02009;000 permutations simultaneously for single markers and haplotypes, which resulted in empiric <italic>P</italic> = 0.04 and <italic>P</italic> = 0.02 for rs1800469 and rs1982073, respectively. A relatively high degree of linkage disequilibrium (LD) was detected in this locus, which resulted in 5 observed out of 32 expected haplotypes, which made it relatively easy to reveal genetic variability with the selected number of SNPs. Two out of five marker haplotypes, TGGCG and CTGTA, showed a significant difference between male patients and male controls (<italic>P</italic> = 0.0012 and <italic>P</italic>&#x000a0;= 0.0018, respectively, Table <xref ref-type="table" rid="T5">5</xref>a), and these two haplotypes passed the permutation test with empiric <italic>P</italic> = 0.006 and 0.008, respectively. These haplotypes represent either protective (TGGCG) or susceptible (CTGTA) variants and are opposite in four out of five alleles. The protective TGGCG haplotype comprises 56.4% of all chromosomes in the control male population and the CTGTA represents only 5.7%. The former number corresponds to 90% and the latter to 86% power of analysis to detect significant difference at 0.05 threshold in the two-tailed test. We found no indication for an association of <italic>TGFB1</italic> gene polymorphism with disease in females in the allelic model nor in the haplotype analysis for this study group (Tables <xref ref-type="table" rid="T4">4</xref>b and <xref ref-type="table" rid="T5">5</xref>b).</p><table-wrap id="T4" position="float"><label>Table&#x000a0;4</label><caption><p>Allelic frequencies of <italic>TGFB1</italic> polymorphisms in (a) male and (b) female IgA nephropathy patients and healthy controls</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Control, case</th><th align="left" rowspan="1" colspan="1">Control, case</th><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">100&#x02009;000 permutation,</th></tr><tr><th align="left" rowspan="1" colspan="1">SNPs</th><th align="left" rowspan="1" colspan="1">ratio counts</th><th align="left" rowspan="1" colspan="1">frequencies</th><th align="left" rowspan="1" colspan="1">Chi-square</th><th align="left" rowspan="1" colspan="1"><italic>P</italic>-value<sup>a</sup></th><th align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td colspan="6" align="left" rowspan="1">(a) Male IgA nephropathy patients</td></tr><tr><td rowspan="1" colspan="1">rs6957</td><td rowspan="1" colspan="1">537:91, 228:60</td><td rowspan="1" colspan="1">0.855, 0.792</td><td rowspan="1" colspan="1">5.77</td><td rowspan="1" colspan="1">0.016</td><td rowspan="1" colspan="1">0.08</td></tr><tr><td rowspan="1" colspan="1">rs2241715</td><td rowspan="1" colspan="1">462:168, 191:99</td><td rowspan="1" colspan="1">0.733, 0.659</td><td rowspan="1" colspan="1">5.381</td><td rowspan="1" colspan="1">0.020</td><td rowspan="1" colspan="1">0.09</td></tr><tr><td rowspan="1" colspan="1">rs1800471</td><td rowspan="1" colspan="1">581:47, 259:27</td><td rowspan="1" colspan="1">0.925, 0.906</td><td rowspan="1" colspan="1">1.011</td><td rowspan="1" colspan="1">0.314</td><td rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">rs1982073</td><td rowspan="1" colspan="1">411:217, 158:130</td><td rowspan="1" colspan="1">0.654, 0.549</td><td rowspan="1" colspan="1">9.401</td><td rowspan="1" colspan="1">0.002</td><td rowspan="1" colspan="1">0.02</td></tr><tr><td rowspan="1" colspan="1">rs1800469</td><td rowspan="1" colspan="1">460:168, 186:102</td><td rowspan="1" colspan="1">0.732, 0.646</td><td rowspan="1" colspan="1">7.132</td><td rowspan="1" colspan="1">0.007</td><td rowspan="1" colspan="1">0.04</td></tr><tr><td colspan="6" align="left" rowspan="1">(b) Female IgA nephropathy patients</td></tr><tr><td rowspan="1" colspan="1">rs6957</td><td rowspan="1" colspan="1">52:252, 22:108</td><td rowspan="1" colspan="1">0.171, 0.169</td><td rowspan="1" colspan="1">0.002</td><td rowspan="1" colspan="1">0.9631</td><td rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">rs2241715</td><td rowspan="1" colspan="1">92:214, 34:98</td><td rowspan="1" colspan="1">0.301, 0.258</td><td rowspan="1" colspan="1">0.835</td><td rowspan="1" colspan="1">0.3608</td><td rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">rs1800471</td><td rowspan="1" colspan="1">285:23, 120:12</td><td rowspan="1" colspan="1">0.925, 0.909</td><td rowspan="1" colspan="1">0.333</td><td rowspan="1" colspan="1">0.5641</td><td rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">rs1982073</td><td rowspan="1" colspan="1">116:190, 49:83</td><td rowspan="1" colspan="1">0.379, 0.371</td><td rowspan="1" colspan="1">0.024</td><td rowspan="1" colspan="1">0.876</td><td rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">rs1800469</td><td rowspan="1" colspan="1">93:215, 36:94</td><td rowspan="1" colspan="1">0.302, 0.277</td><td rowspan="1" colspan="1">0.276</td><td rowspan="1" colspan="1">0.5996</td><td rowspan="1" colspan="1">NS</td></tr></tbody></table><table-wrap-foot><fn id="T4TFN1"><p><sup>a</sup>Uncorrected.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T5" position="float"><label>Table&#x000a0;5</label><caption><p>Haplotype frequencies of <italic>TGFB1</italic> polymorphisms in (a) male and (b) female IgA nephropathy patients and healthy controls</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Haplotype</th><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Control/case</th><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">100&#x02009;000 permutation</th></tr><tr><th align="left" rowspan="1" colspan="1">Block</th><th align="left" rowspan="1" colspan="1">frequencies</th><th align="left" rowspan="1" colspan="1">Control/case ratio counts</th><th align="left" rowspan="1" colspan="1">frequencies</th><th align="left" rowspan="1" colspan="1">Chi-square</th><th align="left" rowspan="1" colspan="1"><italic>P</italic>-value<sup>a</sup></th><th align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td colspan="7" align="left" rowspan="1">(a) Male IgA nephropathy patients</td></tr><tr><td rowspan="1" colspan="1">TGGCG</td><td rowspan="1" colspan="1">0.528</td><td rowspan="1" colspan="1">355.5: 274.5, 130.5: 159.5</td><td rowspan="1" colspan="1">0.564, 0.450</td><td rowspan="1" colspan="1">10.42</td><td rowspan="1" colspan="1">0.0012</td><td rowspan="1" colspan="1">0.006</td></tr><tr><td rowspan="1" colspan="1">TTGTA</td><td rowspan="1" colspan="1">0.214</td><td rowspan="1" colspan="1">131.1: 498.9, 65.5: 224.5</td><td rowspan="1" colspan="1">0.208, 0.226</td><td rowspan="1" colspan="1">0.374</td><td rowspan="1" colspan="1">0.5411</td><td rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">CGGCG</td><td rowspan="1" colspan="1">0.089</td><td rowspan="1" colspan="1">55.5: 574.5, 26.5: 263.5</td><td rowspan="1" colspan="1">0.088, 0.091</td><td rowspan="1" colspan="1">0.026</td><td rowspan="1" colspan="1">0.8709</td><td rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">TGCTG</td><td rowspan="1" colspan="1">0.080</td><td rowspan="1" colspan="1">47.0: 583.0, 27.0: 263.0</td><td rowspan="1" colspan="1">0.075, 0.093</td><td rowspan="1" colspan="1">0.919</td><td rowspan="1" colspan="1">0.3378</td><td rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">CTGTA</td><td rowspan="1" colspan="1">0.075</td><td rowspan="1" colspan="1">35.9: 594.1, 33.5: 256.5</td><td rowspan="1" colspan="1">0.057, 0.116</td><td rowspan="1" colspan="1">9.749</td><td rowspan="1" colspan="1">0.0018</td><td rowspan="1" colspan="1">0.008</td></tr><tr><td colspan="7" align="left" rowspan="1">(b) Female IgA nephropathy patients</td></tr><tr><td rowspan="1" colspan="1">TGGCG</td><td rowspan="1" colspan="1">0.526</td><td rowspan="1" colspan="1">161.8: 146.2, 69.6: 62.4</td><td rowspan="1" colspan="1">0.525, 0.527</td><td rowspan="1" colspan="1">0.001</td><td rowspan="1" colspan="1">0.9709</td><td rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">TTGTA</td><td rowspan="1" colspan="1">0.220</td><td rowspan="1" colspan="1">69.4: 238.6, 27.2: 104.8</td><td rowspan="1" colspan="1">0.225, 0.206</td><td rowspan="1" colspan="1">0.194</td><td rowspan="1" colspan="1">0.6599</td><td rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">CGGCG</td><td rowspan="1" colspan="1">0.092</td><td rowspan="1" colspan="1">27.2: 280.8, 13.4: 118.6</td><td rowspan="1" colspan="1">0.088, 0.101</td><td rowspan="1" colspan="1">0.194</td><td rowspan="1" colspan="1">0.6595</td><td rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">TGCTG</td><td rowspan="1" colspan="1">0.070</td><td rowspan="1" colspan="1">19.8: 288.2, 10.9: 121.1</td><td rowspan="1" colspan="1">0.064, 0.082</td><td rowspan="1" colspan="1">0.455</td><td rowspan="1" colspan="1">0.4998</td><td rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">CTGTA</td><td rowspan="1" colspan="1">0.064</td><td rowspan="1" colspan="1">21.6: 286.4, 6.8: 125.2</td><td rowspan="1" colspan="1">0.070, 0.051</td><td rowspan="1" colspan="1">0.545</td><td rowspan="1" colspan="1">0.4602</td><td rowspan="1" colspan="1">NS</td></tr></tbody></table><table-wrap-foot><fn id="T5TFN1"><p><sup>a</sup>Uncorrected.</p></fn></table-wrap-foot></table-wrap></sec><sec id="S3-2"><title>Correlations between genotypes and progression of IgA nephropathy</title><p>Using the disease severity criteria defined in the &#x02018;Materials and methods&#x02019; section in 95 patients with available clinical data, 52 (54.7%) patients were classified as having benign disease, 19 (20%) patients had moderate renal disease progression and 24 (25.3%) patients had severe renal disease progression. No significant differences in genotype frequencies in either the co-dominant model or the dominant/recessive model were observed among the different severity groups with or without stratification for gender (data not shown).</p></sec><sec id="S3-3"><title>Meta-analysis</title><p>By searching information from PubMed and ISI Web of Knowledge, we found four published articles related to <italic>TGFB1</italic> gene polymorphisms in IgA nephropathy in four different populations: Korean, Japanese, Italian and German [<xref ref-type="bibr" rid="R9 R10">9,10</xref>,<xref ref-type="bibr" rid="R13 R14">13,14</xref>]. No additional data were found in abstracts or proceedings. All papers had used similar selection criteria for IgA nephropathy patients compared to our study; however, selection of control groups differed from our study and stratification for gender was not done. Only in the study by Carturan <italic>et al</italic>., the control group was age- and gender-matched. In the study of Bantis <italic>et al</italic>., controls were matched by age, but not by gender. In the studies by Sato <italic>et al</italic>. and Lim <italic>et al</italic>., the control groups were discordant for age and for gender ratio. All studies except that by Carturan <italic>et al</italic>. reported that individuals in the control groups were of the same ethnicity as the patient groups. At least two <italic>TGFB1</italic> polymorphisms (rs1982073 and rs1800469) were investigated in three studies [<xref ref-type="bibr" rid="R9 R10">9,10</xref>,<xref ref-type="bibr" rid="R13">13</xref>]. Two studies [<xref ref-type="bibr" rid="R10">10</xref>,<xref ref-type="bibr" rid="R13">13</xref>] were included in meta-analysis together with our data for these <italic>TGFB1</italic> markers. In the remaining study [<xref ref-type="bibr" rid="R9">9</xref>], the frequency of the genotype distribution for the rs1982073 significantly deviated from Hardy&#x02013;Weinberg equilibrium, which questions the validity of the data. For this reason, we decided to exclude this particular study from the meta-analysis. As we could only use the frequency of variations for the combined group of both genders in the previously published studies, our own data were also not stratified by gender for the meta-analysis. The Mantel&#x02013;Haenszel method with fixed effect demonstrated a significant cumulative odds ratio for rs1982073 (0.77, 95% CI 0.61&#x02013;0.97) (Figure <xref ref-type="fig" rid="F1">1</xref>), suggesting that the <italic>TGFB1</italic> gene polymorphism is associated with IgA nephropathy in the studied populations. In addition, rs1800469 showed a trend for association with disease susceptibility, which did not reach statistical significance in the meta-analysis (0.86, 95% CI 0.69&#x02013;1.07). Both genetic markers displayed a protective effect for the common genotype (CC and GG respectively) and passed the test for heterogeneity between the studies.</p><fig id="F1" position="float"><label>Fig. 1</label><caption><p>Meta-analysis with rs1800469 in two different populations and our own data; the genetic marker displayed a protective effect for the common genotype with CC and passed test for heterogeneity between the studies.</p></caption><graphic xlink:href="gfp079fig1"/></fig></sec></sec><sec id="S4" sec-type="discussion"><title>Discussion</title><p>In the present study, we demonstrate an association of the <italic>TGFB1</italic> gene polymorphism with IgA nephropathy. Our own data, together with the meta-analysis of previously published data, provide a strong indication of the importance of TGF&#x003b2;1 in the development of IgA nephropathy.</p><p>Previously, both linkage and association studies have been utilized to study the susceptibility risk factors for IgA nephropathy. Using genome-wide linkage microsatellite analysis, a linkage of IgA nephropathy to 2q36, 6q22&#x02013;23, 4q26&#x02013;31 and 17q12&#x02013;22 has been suggested [<xref ref-type="bibr" rid="R3">3</xref>,<xref ref-type="bibr" rid="R19 R20 R21 R22">19&#x02013;22</xref>]. However, no obvious candidate genes within these linkage regions have so far been identified. Several candidate gene polymorphism association studies have previously been performed to explore the role of several genes that could be related to the susceptibility to and the progression of IgA nephropathy, including MHC class II [<xref ref-type="bibr" rid="R23">23</xref>], T-cell receptor &#x003b1; and &#x003b2; [<xref ref-type="bibr" rid="R24 R25 R26">24&#x02013;26</xref>], uteroglobin [<xref ref-type="bibr" rid="R27 R28">27,28</xref>], angiotensin-converting enzyme (ACE) [<xref ref-type="bibr" rid="R29 R30">29,30</xref>], other renin&#x02013;angiotensin system genes [<xref ref-type="bibr" rid="R31 R32">31,32</xref>], as well as several cytokine genes [<xref ref-type="bibr" rid="R33">33</xref>]. However, some of these studies have shown contradictory results, and larger patient populations with an optimal study design are required to establish the role of specific genes in the susceptibility to IgA nephropathy. Although most studies used ethnically homogeneous study populations, the gender effect was not assessed in any of those investigations.</p><p>In our analysis of five <italic>TGFB1</italic> gene polymorphisms in a cohort of 212 patients with IgA nephropathy and 477 age-, gender- and ethnicity-matched controls, we were able to demonstrate, with reasonable statistical power, an association between genetic variations in the <italic>TGFB1</italic> gene and the susceptibility to IgA nephropathy in males. A meta-analysis of previously published data from two independent studies together with our results strengthens this conclusion.</p><p>There are four previous studies addressing the importance of the <italic>TGFB1</italic> gene in IgA nephropathy in four different populations [<xref ref-type="bibr" rid="R9 R10">9,10</xref>,<xref ref-type="bibr" rid="R13 R14">13,14</xref>]. In the study performed in 329 Japanese patients with IgA nephropathy, two <italic>TGFB1</italic> gene polymorphisms (rs1982073 and rs1800469) were shown to associate with heavy proteinuria and mesangial glomerular proliferation. This is at the moment the largest published genetic study of IgA nephropathy. However, no association with susceptibility to IgA nephropathy was demonstrated [<xref ref-type="bibr" rid="R10">10</xref>]. In the study from South Korea, analysing two SNPs, C-509T and T869C (rs1982073 and rs1800469), a significant difference in the genotype frequency was found comparing 108 patients with IgA nephropathy and healthy controls [<xref ref-type="bibr" rid="R9">9</xref>]. Since the reported frequencies of the rs1800469 genotypes significantly deviated from Hardy&#x02013;Weinberg equilibrium, these data have to be taken with some caution. Two other studies were done in Europe in Caucasians with IgA nephropathy. In the study performed in Germany, one <italic>TGFB1</italic> SNP, rs1800471 (C915G or codon 25, arginine&#x02192;proline), showed the similar genotype distribution between IgA nephropathy patients and controls as well as between the progression and non-progression groups [<xref ref-type="bibr" rid="R14">14</xref>]. Finally, in an Italian study, three <italic>TGFB1</italic> SNPs, Leu10&#x02192;Pro (rs1982073), C-509T (rs1800469) and G-800A (rs1800468), were investigated in 101 patients with IgA nephropathy and 118 healthy controls [<xref ref-type="bibr" rid="R13">13</xref>]. A significant association was observed in the haplotype analysis, but genotype frequencies did not reach significant statistical difference.</p><p>Three previous studies have demonstrated either a tendency for an association or a significant association with at least some genetic markers in the <italic>TGFB1</italic> gene. We performed a meta-analysis in order to further test the role of <italic>TGFB1</italic> in the susceptibility to IgA nephropathy. In the meta-analysis, we combined our new findings and data with those obtained in two of the previously published studies [<xref ref-type="bibr" rid="R10">10</xref>,<xref ref-type="bibr" rid="R13">13</xref>] and included two genetic markers (rs1982073 and rs1800469) that were investigated in all of the studies. Due to the fact that data in previous studies could not be stratified by gender, we combined the female and male groups in our study into one group for this specific test. This meta-analysis supported the role of the <italic>TGFB1</italic> gene in the development of IgA nephropathy in a combined group of 640 IgA nephropathy patients and 880 controls with a <italic>post hoc</italic> power estimate of 96% for the one-tailed test. However, this must be taken with caution due to a possible bias towards publishing of positive associations. It is also important to perform further extension of the study to get better statistical power to detect an association. Another way of addressing a lack of power could be replication of the association in independent cohorts.</p><p>However, it is possibly premature to claim functional consequences from any of the analysed variations, due to a strong pattern of LD in this region. In fact, three markers from our study (rs1800469, rs1982073 and rs1800471) belong to the recombination block with high LD (D&#x02032;&#x02248;1.0), which means that any variation in this region may be in association with a certain phenotype, because of its close position to the mutual causal allele. This is a strong indication of either a true importance of the combination of common alleles, which were selected for our study, or for an unknown causal variation, which is in high LD with the analysed single-nucleotide polymorphisms (SNPs). In both cases, it is evident that genetic variations in the <italic>TGFB1</italic> locus could be important contributors to disease development. It is also noteworthy to mention that the genetic landscape of variations in this locus seems to be very different in Caucasian and Chinese or Japanese populations and allelic frequencies are significantly different [<xref ref-type="bibr" rid="R34 R35">34,35</xref>]. This must be taken into account in future studies of different patient populations. We excluded non-Caucasians from the current study to avoid extensive population admixture, but a proper genomic control in our study was not possible due to the limited number of included SNPs. Another potential difficulty is the failure in genotyping of some variations in this locus: out of nine tested SNP assays only four demonstrated a robust performance and were selected for our genetic study, which may illustrate either a high homology of sequences flanking these variations with other genetic regions or a high frequency of copy number polymorphisms in this locus.</p><p>In our study, no significant differences in genotype frequencies between the non-progression and the progression groups of IgA nephropathy patients with impaired renal function could be demonstrated.</p><p>In summary, by using our own experimental data and a meta-analysis of previously published data, we propose that the <italic>TGFB1</italic> gene is an important contributor for the susceptibility to IgA nephropathy. Additional replication for such association and further studies are warranted to investigate disease mechanisms and the physiological role of <italic>TGFB1</italic> in the development of kidney diseases. Moreover, we suggest considering the effect of gender in such studies.</p></sec></body><back><ack><p>We would like to thank Eva Jemseby, Per-Anton Westerberg, Susanne Schepull, Micael Gylling and Per Eriksson for their helpful assistance. Dr Jarl Ahlm&#x000e9;n's involvement at the initial stage of this study is highly appreciated. We are grateful for the support by the Sida/SAREC, Roche, and The Fund for Renal Research (Heart and Lung Foundation), Sweden.</p><p><italic>Conflict of interest statement</italic>. None declared.</p><p>(See related article by M. Barua and Y. Pei. Identifying susceptibility genes of IgA nephropathy: research in progress. <italic>Nephrol Dial Transplant</italic> 2009; 24: 2957&#x02013;2959.)</p></ack><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schena</surname><given-names>FP</given-names></name></person-group><article-title>A retrospective analysis of the natural history of primary IgA nephropathy worldwide</article-title><source>Am J Med</source><year>1990</year><volume>89</volume><fpage>209</fpage><lpage>215</lpage><pub-id pub-id-type="pmid">2200265</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x02019;Amico</surname><given-names>G</given-names></name></person-group><article-title>Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors</article-title><source>Am J Kidney Dis</source><year>2000</year><volume>36</volume><fpage>227</fpage><lpage>237</lpage><pub-id pub-id-type="pmid">10922300</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Julian</surname><given-names>BA</given-names></name><name><surname>Quiggins</surname><given-names>PA</given-names></name><name><surname>Thompson</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Familial IgA nephropathy. Evidence of an inherited mechanism of disease</article-title><source>N Engl J Med</source><year>1985</year><volume>312</volume><fpage>202</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">3855328</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donadio</surname><given-names>JV</given-names></name><name><surname>Grande</surname><given-names>JP</given-names></name></person-group><article-title>IgA nephropathy</article-title><source>N Engl J Med</source><year>2002</year><volume>347</volume><fpage>738</fpage><lpage>748</lpage><pub-id pub-id-type="pmid">12213946</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>SR</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>PH</given-names></name></person-group><article-title>Smad3 and Smad4 mediate transforming growth factor-beta1-induced IgA expression in murine B lymphocytes</article-title><source>Eur J Immunol</source><year>2001</year><volume>31</volume><fpage>1706</fpage><lpage>1715</lpage><pub-id pub-id-type="pmid">11385614</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Border</surname><given-names>WA</given-names></name><name><surname>Ruoslahti</surname><given-names>E</given-names></name></person-group><article-title>Transforming growth factor-beta in disease: the dark side of tissue repair</article-title><source>J Clin Invest</source><year>1992</year><volume>90</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">1634602</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Border</surname><given-names>WA</given-names></name></person-group><article-title>Transforming growth factor-beta and the pathogenesis of glomerular diseases</article-title><source>Curr Opin Nephrol Hypertens</source><year>1994</year><volume>3</volume><fpage>54</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">7850412</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coll</surname><given-names>E</given-names></name><name><surname>Cormand</surname><given-names>B</given-names></name><name><surname>Campos</surname><given-names>B</given-names></name><etal/></person-group><article-title>Association of TGF-beta1 polymorphisms with chronic renal disease</article-title><source>J Nephrol</source><year>2004</year><volume>17</volume><fpage>794</fpage><lpage>799</lpage><pub-id pub-id-type="pmid">15593053</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>CS</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name><name><surname>Chae</surname><given-names>DW</given-names></name><etal/></person-group><article-title>Association of C-509T and T869C polymorphisms of transforming growth factor-beta1 gene with susceptibility to and progression of IgA nephropathy</article-title><source>Clin Nephrol</source><year>2005</year><volume>63</volume><fpage>61</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">15730046</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>F</given-names></name><name><surname>Narita</surname><given-names>I</given-names></name><name><surname>Goto</surname><given-names>S</given-names></name><etal/></person-group><article-title>Transforming growth factor-beta1 gene polymorphism modifies the histological and clinical manifestations in Japanese patients with IgA nephropathy</article-title><source>Tissue Antigens</source><year>2004</year><volume>64</volume><fpage>35</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">15191521</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xaubet</surname><given-names>A</given-names></name><name><surname>Marin-Arguedas</surname><given-names>A</given-names></name><name><surname>Lario</surname><given-names>S</given-names></name><etal/></person-group><article-title>Transforming growth factor-beta1 gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis</article-title><source>Am J Respir Crit Care Med</source><year>2003</year><volume>168</volume><fpage>431</fpage><lpage>435</lpage><pub-id pub-id-type="pmid">12746254</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Awad</surname><given-names>MR</given-names></name><name><surname>El-Gamel</surname><given-names>A</given-names></name><name><surname>Hasleton</surname><given-names>P</given-names></name><etal/></person-group><article-title>Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation</article-title><source>Transplantation</source><year>1998</year><volume>66</volume><fpage>1014</fpage><lpage>1020</lpage><pub-id pub-id-type="pmid">9808485</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carturan</surname><given-names>S</given-names></name><name><surname>Roccatello</surname><given-names>D</given-names></name><name><surname>Menegatti</surname><given-names>E</given-names></name><etal/></person-group><article-title>Association between transforming growth factor beta1 gene polymorphisms and IgA nephropathy</article-title><source>J Nephrol</source><year>2004</year><volume>17</volume><fpage>786</fpage><lpage>793</lpage><pub-id pub-id-type="pmid">15593052</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bantis</surname><given-names>C</given-names></name><name><surname>Heering</surname><given-names>P</given-names></name><name><surname>Aker</surname><given-names>S</given-names></name><etal/></person-group><article-title>Influence of cytokine gene polymorphisms on IgA nephropathy</article-title><source>Ren Fail</source><year>2008</year><volume>30</volume><fpage>135</fpage><lpage>140</lpage><pub-id pub-id-type="pmid">18300111</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levey</surname><given-names>AS</given-names></name><name><surname>Bosch</surname><given-names>JP</given-names></name><name><surname>Lewis</surname><given-names>JB</given-names></name><etal/></person-group><collab>Modification of Diet in Renal Disease Study Group</collab><article-title>A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation</article-title><source>Ann Intern Med</source><year>1999</year><volume>130</volume><fpage>461</fpage><lpage>470</lpage><pub-id pub-id-type="pmid">10075613</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Padyukov</surname><given-names>L</given-names></name><name><surname>Hahn-Zoric</surname><given-names>M</given-names></name><name><surname>Blomqvist</surname><given-names>SR</given-names></name><etal/></person-group><article-title>Distribution of human kappa locus IGKV2-29 and IGKV2D-29 alleles in Swedish Caucasians and Hong Kong Chinese</article-title><source>Immunogenetics</source><year>2001</year><volume>53</volume><fpage>22</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">11261927</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Morinobu</surname><given-names>A</given-names></name><name><surname>Kanagawa</surname><given-names>S</given-names></name><etal/></person-group><article-title>Transforming growth factor beta 1 gene polymorphism in Japanese patients with systemic lupus erythematosus</article-title><source>Kobe J Med Sci</source><year>2007</year><volume>53</volume><fpage>15</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">17579298</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Fry</surname><given-names>B</given-names></name><name><surname>Maller</surname><given-names>J</given-names></name><etal/></person-group><article-title>Haploview: analysis and visualization of LD and haplotype maps</article-title><source>Bioinformatics</source><year>2005</year><volume>21</volume><fpage>263</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">15297300</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bisceglia</surname><given-names>L</given-names></name><name><surname>Cerullo</surname><given-names>G</given-names></name><name><surname>Forabosco</surname><given-names>P</given-names></name><etal/></person-group><article-title>Genetic heterogeneity in Italian families with IgA nephropathy: suggestive linkage for two novel IgA nephropathy loci</article-title><source>Am J Hum Genet</source><year>2006</year><volume>79</volume><fpage>1130</fpage><lpage>1134</lpage><pub-id pub-id-type="pmid">17186473</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gharavi</surname><given-names>AG</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Scolari</surname><given-names>F</given-names></name><etal/></person-group><article-title>IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22&#x02013;23</article-title><source>Nat Genet</source><year>2000</year><volume>26</volume><fpage>354</fpage><lpage>357</lpage><pub-id pub-id-type="pmid">11062479</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paterson</surname><given-names>AD</given-names></name><name><surname>Liu</surname><given-names>XQ</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><etal/></person-group><article-title>Genome-wide linkage scan of a large family with IgA nephropathy localizes a novel susceptibility locus to chromosome 2q36</article-title><source>J Am Soc Nephrol</source><year>2007</year><volume>18</volume><fpage>2408</fpage><lpage>2415</lpage><pub-id pub-id-type="pmid">17634434</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Julian</surname><given-names>BA</given-names></name><name><surname>Wyatt</surname><given-names>RJ</given-names></name><name><surname>Matousovic</surname><given-names>K</given-names></name><etal/></person-group><article-title>IgA nephropathy: a clinical overview</article-title><source>Contrib Nephrol</source><year>2007</year><volume>157</volume><fpage>19</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">17495433</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akiyama</surname><given-names>F</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Yamada</surname><given-names>R</given-names></name><etal/></person-group><article-title>Single-nucleotide polymorphisms in the class II region of the major histocompatibility complex in Japanese patients with immunoglobulin a nephropathy</article-title><source>J Hum Genet</source><year>2002</year><volume>47</volume><fpage>532</fpage><lpage>538</lpage><pub-id pub-id-type="pmid">12376743</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batra</surname><given-names>A</given-names></name><name><surname>Smith</surname><given-names>AC</given-names></name><name><surname>Feehally</surname><given-names>J</given-names></name><etal/></person-group><article-title>T-cell homing receptor expression in IgA nephropathy</article-title><source>Nephrol Dial Transplant</source><year>2007</year><volume>22</volume><fpage>2540</fpage><lpage>2548</lpage><pub-id pub-id-type="pmid">17452405</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deenitchina</surname><given-names>SS</given-names></name><name><surname>Shinozaki</surname><given-names>M</given-names></name><name><surname>Hirano</surname><given-names>T</given-names></name><etal/></person-group><article-title>Association of a T-cell receptor constant alpha chain gene polymorphism with progression of IgA nephropathy in Japanese patients</article-title><source>Am J Kidney Dis</source><year>1999</year><volume>34</volume><fpage>279</fpage><lpage>288</lpage><pub-id pub-id-type="pmid">10430975</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>PK</given-names></name><name><surname>Poon</surname><given-names>P</given-names></name><name><surname>Phil</surname><given-names>M</given-names></name><etal/></person-group><article-title>Association of IgA nephropathy with T-cell receptor constant alpha chain gene polymorphism</article-title><source>Am J Kidney Dis</source><year>1997</year><volume>30</volume><fpage>260</fpage><lpage>264</lpage><pub-id pub-id-type="pmid">9261038</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsunaga</surname><given-names>A</given-names></name><name><surname>Numakura</surname><given-names>C</given-names></name><name><surname>Kawakami</surname><given-names>T</given-names></name><etal/></person-group><article-title>Association of the uteroglobin gene polymorphism with IgA nephropathy</article-title><source>Am J Kidney Dis</source><year>2002</year><volume>39</volume><fpage>36</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">11774099</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shijubo</surname><given-names>N</given-names></name><name><surname>Kawabata</surname><given-names>I</given-names></name><name><surname>Sato</surname><given-names>N</given-names></name><etal/></person-group><article-title>Clinical aspects of Clara cell 10-kDa protein/uteroglobin (secretoglobin 1A1)</article-title><source>Curr Pharm Des</source><year>2003</year><volume>9</volume><fpage>1139</fpage><lpage>1149</lpage><pub-id pub-id-type="pmid">12769755</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coppo</surname><given-names>R</given-names></name><name><surname>Amore</surname><given-names>A</given-names></name><name><surname>Peruzzi</surname><given-names>L</given-names></name><etal/></person-group><article-title>Angiotensin antagonists and fish oil for treating IgA nephropathy</article-title><source>Contrib Nephrol</source><year>2007</year><volume>157</volume><fpage>27</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">17495434</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Locatelli</surname><given-names>F</given-names></name><name><surname>Vecchio</surname><given-names>LD</given-names></name><name><surname>Pozzi</surname><given-names>C</given-names></name></person-group><article-title>IgA glomerulonephritis: beyond angiotensin-converting enzyme inhibitors</article-title><source>Nat Clin Pract Nephrol</source><year>2006</year><volume>2</volume><fpage>24</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">16932386</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maruyama</surname><given-names>K</given-names></name><name><surname>Yoshida</surname><given-names>M</given-names></name><name><surname>Nishio</surname><given-names>H</given-names></name><etal/></person-group><article-title>Polymorphisms of renin-angiotensin system genes in childhood IgA nephropathy</article-title><source>Pediatr Nephrol</source><year>2001</year><volume>16</volume><fpage>350</fpage><lpage>355</lpage><pub-id pub-id-type="pmid">11354780</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ong-Ajyooth</surname><given-names>S</given-names></name><name><surname>Ong-Ajyooth</surname><given-names>L</given-names></name><name><surname>Limmongkon</surname><given-names>A</given-names></name><etal/></person-group><article-title>The renin&#x02013;angiotensin system gene polymorphisms and clinicopathological correlations in IgA nephropathy</article-title><source>J Med Assoc Thai</source><year>1999</year><volume>82</volume><fpage>681</fpage><lpage>689</lpage><pub-id pub-id-type="pmid">10511770</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wada</surname><given-names>J</given-names></name><name><surname>Sugiyama</surname><given-names>H</given-names></name><name><surname>Makino</surname><given-names>H</given-names></name></person-group><article-title>Pathogenesis of IgA nephropathy</article-title><source>Semin Nephrol</source><year>2003</year><volume>23</volume><fpage>556</fpage><lpage>563</lpage><pub-id pub-id-type="pmid">14631563</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>Y</given-names></name><name><surname>Kinoshita</surname><given-names>A</given-names></name><name><surname>Yamada</surname><given-names>T</given-names></name><etal/></person-group><article-title>A catalog of 106 single-nucleotide polymorphisms (SNPs) and 11 other types of variations in genes for transforming growth factor-beta1 (TGF-beta1) and its signaling pathway</article-title><source>J Hum Genet</source><year>2002</year><volume>47</volume><fpage>478</fpage><lpage>483</lpage><pub-id pub-id-type="pmid">12202987</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohtsuka</surname><given-names>T</given-names></name><name><surname>Yamakage</surname><given-names>A</given-names></name><name><surname>Yamazaki</surname><given-names>S</given-names></name></person-group><article-title>The polymorphism of transforming growth factor-beta1 gene in Japanese patients with systemic sclerosis</article-title><source>Br J Dermatol</source><year>2002</year><volume>147</volume><fpage>458</fpage><lpage>463</lpage><pub-id pub-id-type="pmid">12207584</pub-id></element-citation></ref></ref-list></back></article>